CJC-1295 vs Mod GRF 1-29: which GHRH analogue holds up

Last updated 2026-07-26

What is the actual difference between CJC-1295 and Mod GRF 1-29?

Both molecules are analogues of growth hormone releasing hormone (GHRH), built off the first 29 or 30 amino acids of the native 44-residue hormone, which is the fragment that retains full biological activity. Native GHRH itself is degraded in minutes by the enzyme dipeptidyl peptidase-4 (DPP-4) and by other serum proteases, which is why nobody uses unmodified GHRH(1-29) for anything practical. CJC-1295 was developed academically as DAC:GRF, a GRF(1-29) analogue carrying four amino acid substitutions (to resist DPP-4 and other degradation) plus a Drug Affinity Complex (DAC), a maleimidopropionic acid linker that covalently binds circulating albumin. That albumin binding is what gives the DAC version its long half-life. The original human study, published in the Journal of Clinical Endocrinology and Metabolism, described the compound as a "long-acting growth hormone-releasing factor (GRF) analog" and reported that a single 30 mcg/kg dose in healthy adults raised GH levels for six days and increased IGF-1 levels for up to 9 to 11 days ^[1]. Mod GRF 1-29, also called CJC-1295 without DAC or tetrasubstituted GRF(1-29), is essentially the same four-substitution peptide backbone, minus the DAC tail. Without the albumin anchor, it behaves like a modestly stabilized version of the native 1-29 fragment: still degraded relatively quickly, but slower than unmodified GHRH. This is the source of a lot of naming confusion online. "CJC-1295" sometimes gets used loosely to mean either version, but chemically they are two different molecules with two different clearance profiles. For dosing specifics on the DAC version, see CJC-1295 with DAC. A side note some bodybuilding forums get wrong: Mod GRF 1-29 is not identical to sermorelin. Sermorelin is GHRH(1-29) with no stabilizing substitutions at all, and it clears even faster, with a reported plasma half-life of about 10 to 20 minutes depending on the source and assay ^[2]. Mod GRF 1-29's four substitutions push that a bit further, commonly cited around 30 minutes, though that figure comes from pharmacokinetic modeling and manufacturer/peptide-chemistry literature rather than a large published human trial specific to the modified 1-29 fragment.

How does the half-life difference change how you'd dose each one?

This is the whole ballgame. Half-life determines dosing frequency, and dosing frequency determines whether you're chasing a GH pulse or trying to hold a low, steady elevation. CJC-1295 with DAC, because of its multi-day half-life, is dosed infrequently, often once or twice weekly in the protocols described in peptide literature and the original PK study ^[1]. The tradeoff is that it doesn't produce a sharp, discrete GH pulse the way natural physiology does; it more closely mimics a sustained, blunted elevation. Some researchers and clinicians have raised the concern that a non-pulsatile GH elevation isn't how the body's feedback loops (GHRH, somatostatin, ghrelin) are built to operate, though there isn't a definitive human outcomes study settling whether that structural difference matters clinically. Mod GRF 1-29 and CJC-1295 without DAC, with their roughly 30-minute half-life, are dosed multiple times per day, typically once or more daily and often timed around sleep onset or training, precisely because the effect window is short. This is closer in shape to how GHRH pulses occur physiologically, which is the main argument people make for using the short-acting version paired with a ghrelin mimetic. See the CJC-1295 dosage breakdown and, for the DAC-specific math, the CJC-1295 DAC dosage calculator. Here's the comparison in one place. | Attribute | CJC-1295 with DAC | Mod GRF 1-29 (CJC-1295 no DAC) |

Is Mod GRF 1-29 the same thing as GRF 1-29 or sermorelin?

No, and this is where a lot of vendor copy gets sloppy. Native GRF(1-29), also written GHRH(1-29), is the unmodified fragment; it is degraded very quickly by DPP-4 and other proteases in serum, which limits its usefulness as an injectable. Sermorelin is the pharmaceutical name historically used for synthetic GHRH(1-29), the same unmodified sequence. It was studied and marketed for diagnostic and pediatric growth hormone deficiency use, with clinical pharmacology describing it as an agent that stimulates GH release by acting on pituitary somatotrophs ^[2]. Mod GRF 1-29 (tetrasubstituted GRF 1-29) takes that same 1-29 backbone and adds four amino acid substitutions designed to slow enzymatic degradation. It is not FDA-approved for any indication, is not sold as sermorelin, and the stability data on it comes largely from peptide chemistry and preclinical work rather than a dedicated human PK trial published in a flagship journal. Treat vendor half-life claims for Mod GRF 1-29 as reasonable estimates, not settled numbers.

Which one is better paired with ipamorelin, and why does that pairing exist at all?

Ipamorelin is a ghrelin receptor agonist (a growth hormone secretagogue), a completely different mechanism from GHRH analogues. GHRH analogues (CJC-1295, Mod GRF 1-29, sermorelin) work on the GHRH receptor on pituitary somatotrophs; ghrelin mimetics like ipamorelin work on the GHSR-1a receptor and also suppress somatostatin, the hormone that normally puts the brakes on GH release. The rationale for combining a GHRH analogue with a ghrelin mimetic is mechanistic, not built from a large randomized outcome trial. Preclinical and some human pharmacodynamic work on GHRH-plus-GHRP combinations generally shows a synergistic (more than additive) GH response compared to either compound alone, because the two pathways act on somatotrophs through different, partially non-overlapping mechanisms ^[3]. That's real receptor pharmacology. What isn't established by strong long-term human trials is that this translates into a specific, predictable clinical benefit (fat loss, muscle gain, sleep quality) at the doses and frequencies commonly used outside of medical supervision. In practice, people running Mod GRF 1-29 tend to pair it with ipamorelin dosed at the same time, since both are short-acting and both work by producing a discrete pulse, roughly mimicking a natural GH pulse. People running CJC-1295 with DAC sometimes still add a daily ghrelin mimetic on top of the twice-weekly DAC dose, on the theory that DAC provides a sustained floor while ipamorelin adds pulses on top of it. This is plausible pharmacology, but there's no large clinical trial comparing outcomes across these combination strategies head to head. Anyone telling you a specific combination is "proven optimal" is repeating forum consensus, not citing a study.

Which has more actual human research behind it?

CJC-1295 with DAC has the stronger published human data point: the JCEM study by Teichman et al. dosed healthy adults with a single injection and tracked GH and IGF-1 over multiple days, describing dose-dependent increases in both and noting the compound was "generally well tolerated" ^[1]. That's a real, citable, peer-reviewed human trial, though it's a single-dose PK/PD study in a small number of healthy volunteers, not a multi-month efficacy trial for any specific outcome like body composition or strength. Mod GRF 1-29 doesn't have an equivalent dedicated trial under that name. Its supporting evidence is largely inferred from the pharmacology of unmodified GHRH(1-29)/sermorelin, which does have older clinical literature behind it as a GH-stimulation tool ^[2], plus general peptide stability chemistry explaining why amino acid substitutions slow DPP-4 cleavage. That's a reasonable inference, but it's not the same as a trial specifically on the tetrasubstituted analogue. Neither compound is FDA-approved for bodybuilding, anti-aging, or fat-loss use. Both exist almost entirely in the research-chemical and compounding space, which means quality control, dose accuracy, and sterility depend heavily on the source, a separate problem from the pharmacology question this article covers. See CJC-1295 for the broader evidence summary.

What do the side effect profiles look like, and are they different?

Reported side effects for GHRH analogues cluster around a similar list regardless of which version you're looking at: injection site redness or irritation, flushing, headache, dizziness, and the general downstream effects of elevated GH/IGF-1 such as water retention, joint achiness, and in some reports, increased hunger. The original CJC-1295 DAC trial reported the compound as generally well tolerated at the doses studied, with no serious adverse events described in that report ^[1]. Because CJC-1295 with DAC sustains an elevation for days, any side effect tied to elevated GH or IGF-1 (fluid retention, carpal-tunnel-like symptoms, blood sugar shifts) has a longer window to show up and a longer window before it resolves if you stop. Mod GRF 1-29's short half-life means side effects, if they occur, tend to resolve within hours rather than days, simply because the drug clears faster. Neither compound has long-term safety data in the range of years of continuous human use at bodybuilding-style doses. That's a real gap, not a minor caveat. For a fuller rundown of documented and reported effects, see CJC-1295 side effects.

Which one is easier to source correctly, and does purity differ?

Sourcing is arguably the biggest practical risk with both peptides, and it's independent of which molecule you pick. Because neither is FDA-approved for the uses most buyers want, most sourcing happens through research-chemical vendors or compounding pharmacies working from a provider's prescription, and quality varies enormously across that landscape. Mod GRF 1-29, being a smaller, simpler peptide without the DAC/albumin-binding modification, is generally cheaper to synthesize and is widely sold, sometimes under the name "GRF 1-29" or "Mod GRF 1-29" without full clarity on the substitution pattern. CJC-1295 with DAC is a more complex synthesis (the maleimidopropionic acid linker adds a manufacturing step), and mislabeling between the DAC and no-DAC versions is a documented, common problem in the space; buyers regularly report receiving one when they ordered the other, since both are sold under overlapping "CJC-1295" branding. The practical fix is the same regardless of which molecule you choose: work with a source that provides a certificate of analysis, confirms whether DAC is present or absent by name (more than "CJC-1295"), and ideally routes through a provider and a named compounding pharmacy rather than an anonymous research-chemical storefront. For current pricing and source comparisons, see CJC-1295 for sale.

So which one should you actually pick?

If the goal is to mimic natural GH pulsatility as closely as possible and you're fine with more frequent injections, Mod GRF 1-29 (often stacked with ipamorelin) is the more physiologically pulse-like choice, and it's what most of the peptide community defaults to for that reason. If the goal is convenience, fewer injections per week, and you're comfortable with a sustained rather than pulsatile GH elevation, CJC-1295 with DAC has the stronger single published human trial behind its PK/PD claims ^[1], even though that trial doesn't answer questions about months-long use or specific body composition outcomes. Neither choice is a settled "better" option in the clinical literature. This is a real fork in mechanism (pulsatile vs sustained) and a real fork in evidence depth (one dedicated human trial vs extrapolated pharmacology), and reasonable people land on different sides of it depending on how much they weigh injection frequency against physiological pattern-matching. At CJC-1295 Co, our position is straightforward: whichever version you're considering, work from a provider-reviewed protocol and get the peptide filled through a named, accountable compounding pharmacy rather than an unverified research-chemical seller, since sourcing risk is a bigger practical threat to your safety here than the mechanistic differences between the two molecules.

Frequently asked questions

Is Mod GRF 1-29 stronger than CJC-1295 with DAC?

Not in the sense of raw potency per molecule. The real difference is duration: Mod GRF 1-29 clears in about 30 minutes producing a sharper, shorter GH pulse, while CJC-1295 with DAC lasts days, per the original human PK study, producing a lower, sustained elevation ^[1]. "Stronger" depends on whether you mean peak effect or total exposure.

Can I use CJC-1295 and Mod GRF 1-29 together?

They're close chemical relatives (Mod GRF 1-29 is essentially CJC-1295 without the DAC tail), so combining them doesn't add a distinct mechanism the way pairing with ipamorelin does. Most protocols pick one GHRH analogue, not both, and pair it with a separate ghrelin-receptor agonist instead.

Does CJC-1295 without DAC exist, or is that just Mod GRF 1-29?

They're generally treated as the same compound. "CJC-1295 no DAC" and "Mod GRF 1-29" both refer to the tetrasubstituted GRF(1-29) backbone minus the albumin-binding DAC linker. Naming varies by vendor, which is a common source of confusion and mislabeling.

Why does the DAC version last so much longer?

DAC (Drug Affinity Complex) is a chemical linker that covalently binds the peptide to circulating albumin. Albumin has a long half-life in blood, so the attached peptide gets carried along with it, extending GH and IGF-1 elevation to roughly 6 to 11 days after a single dose in the original human study ^[1].

How often do you inject Mod GRF 1-29 versus CJC-1295 with DAC?

Because of its roughly 30-minute half-life, Mod GRF 1-29 is typically dosed once to a few times daily, often timed to sleep or training. CJC-1295 with DAC, with its multi-day half-life, is typically dosed once or twice weekly in protocols derived from its published PK profile ^[1].

Is either of these FDA-approved?

No. Neither CJC-1295 (with or without DAC) nor Mod GRF 1-29 is FDA-approved for any human use. Sermorelin, the unmodified GHRH(1-29) fragment these are derived from, has separate clinical pharmacology literature describing its use as a GH-stimulation test agent ^[2].

Why is CJC-1295 usually paired with ipamorelin instead of used alone?

CJC-1295 acts on the GHRH receptor; ipamorelin acts on the separate ghrelin (GHSR-1a) receptor and suppresses somatostatin. Combining the two mechanisms shows synergistic GH release in pharmacology literature on GHRH-plus-GHRP combinations ^[3], though no large human trial has established a specific clinical outcome from that pairing at typical protocol doses.

What are the main side effects to expect from either peptide?

Reported effects include injection site irritation, flushing, headache, water retention, and joint discomfort tied to elevated GH/IGF-1. The original CJC-1295 DAC trial described the compound as generally well tolerated with no serious adverse events at studied doses ^[1], but long-term human safety data for either peptide is limited.

Is Mod GRF 1-29 the same as sermorelin?

No. Sermorelin is the unmodified GHRH(1-29) sequence with no stabilizing substitutions ^[2]. Mod GRF 1-29 carries four amino acid substitutions meant to resist DPP-4 degradation, giving it a somewhat longer half-life than sermorelin, though both are short-acting compared to the DAC version.

Which peptide has better published human research?

CJC-1295 with DAC has a dedicated peer-reviewed human trial (Teichman et al., Journal of Clinical Endocrinology and Metabolism) measuring GH and IGF-1 after single dosing ^[1]. Mod GRF 1-29 lacks an equivalent named trial; its pharmacology is mostly extrapolated from GHRH(1-29)/sermorelin literature and peptide stability chemistry.

Does injection frequency matter for effectiveness?

It matters for physiological pattern more than for total GH released. Frequent short-acting dosing (Mod GRF 1-29) produces discrete pulses closer to natural GHRH secretion. Infrequent long-acting dosing (CJC-1295 DAC) produces a sustained, blunted elevation. Whether one pattern is clinically better than the other hasn't been settled by a head-to-head human outcomes trial.

Where can I find correct dosing information for either version?

Because the two versions have very different half-lives, dosing schedules are not interchangeable. See the dedicated CJC-1295 dosage guide and the CJC-1295 DAC dosage calculator for version-specific detail rather than applying one schedule to both.

Sources

1. Journal of Clinical Endocrinology & Metabolism, Teichman et al. 2006: Single dose of CJC-1295 (DAC:GRF) raised GH levels for up to 6 days and IGF-1 for 9-11 days, and was generally well tolerated
2. NIH National Library of Medicine, StatPearls: Physiology, Growth Hormone: Sermorelin is the unmodified GHRH(1-29) fragment and GHRH acts on pituitary somatotrophs to stimulate GH release
3. NIH National Library of Medicine, StatPearls: Growth Hormone Releasing Hormone: GHRH analogues and ghrelin-receptor agonists (GHRPs) act via distinct pituitary mechanisms and combined administration produces synergistic GH release
4. PubMed, Sigalos & Pastuszak, "The Safety and Efficacy of Growth Hormone Secretagogues": Growth hormone secretagogues, including GHRH analogues and ghrelin mimetics, are reviewed for mechanism and reported safety profile in human use
5. DrugBank, Tesamorelin (structurally related GHRH analogue) entry: Synthetic GHRH analogues are engineered with amino acid substitutions to resist DPP-4 mediated degradation compared to native GHRH
6. NIH National Library of Medicine, StatPearls: Biochemistry, Dipeptidyl Peptidase IV: DPP-4 is a serum protease responsible for rapid degradation of peptide hormones including GHRH, limiting the half-life of unmodified GHRH(1-29)